Kezar Life Sciences Inc has a consensus price target of $7.2, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on March 15, 2024, December 4, 2023, and November 27, 2023. With an average price target of $20 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 2357.00% upside for Kezar Life Sciences Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/15/2024 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2357% | HC Wainwright & Co. | Raghuram Selvaraju | → $20 | Reiterates | Buy → Buy | Get Alert |
12/04/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2357% | HC Wainwright & Co. | Raghuram Selvaraju | → $20 | Reiterates | Buy → Buy | Get Alert |
11/27/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2357% | HC Wainwright & Co. | Raghuram Selvaraju | → $20 | Reiterates | Buy → Buy | Get Alert |
11/14/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 145.7% | Wells Fargo | Derek Archila | $4 → $2 | Maintains | Equal-Weight | Get Alert |
10/12/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2357% | HC Wainwright & Co. | Raghuram Selvaraju | → $20 | Reiterates | Buy → Buy | Get Alert |
10/05/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | — | JonesTrading | Catherine Novack | — | Downgrade | Buy → Hold | Get Alert |
09/25/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2357% | HC Wainwright & Co. | Raghuram Selvaraju | $18 → $20 | Maintains | Buy | Get Alert |
08/11/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | — | Wells Fargo | Derek Archila | — | Downgrade | Overweight → Equal-Weight | Get Alert |
08/11/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2111.3% | HC Wainwright & Co. | Raghuram Selvaraju | $19 → $18 | Maintains | Buy | Get Alert |
05/12/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2234.15% | HC Wainwright & Co. | Raghuram Selvaraju | $21 → $19 | Maintains | Buy | Get Alert |
05/12/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 1497.05% | Wells Fargo | Derek Archila | $14 → $13 | Maintains | Overweight | Get Alert |
03/16/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | — | William Blair | Matt Phipps | — | Downgrade | Outperform → Market Perform | Get Alert |
03/16/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2479.85% | HC Wainwright & Co. | Raghuram Selvaraju | → $21 | Reiterates | → Buy | Get Alert |
01/03/2023 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 1619.9% | Wells Fargo | Derek Archila | $17 → $14 | Maintains | Overweight | Get Alert |
08/12/2022 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2479.85% | HC Wainwright & Co. | Raghuram Selvaraju | $20 → $21 | Maintains | Buy | Get Alert |
06/28/2022 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 1988.45% | Wells Fargo | Derek Archila | $13 → $17 | Maintains | Overweight | Get Alert |
05/13/2022 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 1497.05% | Wells Fargo | Derek Archila | $14 → $13 | Maintains | Overweight | Get Alert |
05/04/2022 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 1619.9% | Wells Fargo | Derek Archila | $19 → $14 | Maintains | Overweight | Get Alert |
03/18/2022 | KZR | Buy Now | Kezar Life Sciences | $0.81 | 2602.7% | HC Wainwright & Co. | Raghuram Selvaraju | $20 → $22 | Maintains | Buy | Get Alert |
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by HC Wainwright & Co. on March 15, 2024. The analyst firm set a price target for $20.00 expecting KZR to rise to within 12 months (a possible 2357.00% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by HC Wainwright & Co., and Kezar Life Sciences reiterated their buy rating.
There is no last upgrade for Kezar Life Sciences.
The last downgrade for Kezar Life Sciences Inc happened on October 5, 2023 when JonesTrading changed their price target from N/A to N/A for Kezar Life Sciences Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on March 15, 2024 so you should expect the next rating to be made available sometime around March 15, 2025.
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a reiterated with a price target of $0.00 to $20.00. The current price Kezar Life Sciences (KZR) is trading at is $0.81, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.